WELCOME – Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with Omacor Therapy Trial
Principal contacts
Christopher D. Byrne - University of Southampton - Southampton General Hospital, Southampton, UK
Lokpal Bhatia - University of Southampton - Southampton General Hospital, Southampton, UK
Philip C. Calder - University of Southampton - Southampton General Hospital, Southampton, UK
Study design
The Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with Omacor Therapy Trial (WELCOME) is a two-arm clinical trial based in Southampton, UK. The principal aim of the trial was to investigate the effect of Docosahexaenoic acid and Eicosapentaenoic acid (4g/day) versus placebo on atherosclerotic disease in patients with non-alcoholic fatty liver disease. Individuals were eligible for inclusion if they had evidence of liver fat and/or histological confirmation of non-alcoholic fatty liver disease. The study was approved by the Southampton and South West Hampshire NHS Ethics Committee and all participants gave their written informed consent.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00760513
Key publications
Effects of Purified Eicosapentaenoic and Docosahexaenoic Acids in Nonalcoholic Fatty Liver Disease: Results From the WELCOME* Study. Hepatology. 2014 Oct;60(4):1211-21
Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia. 2015 Aug;58(8):1916-25
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. 2016 Mar;246:13-20
Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial. Diabetologia. 2016 Jul;59(7):1422-1429